Gliclazide
SIAL/BP368 - British Pharmacopoeia (BP) Reference Standard
Synonym: 1-
CAS Number: 21187-98-4
Empirical Formula (Hill Notation): C15H21N3O3S
Molecular Weight: 323.41
EC Number: 244-260-5
MDL Number: MFCD00409893
Linear Formula: C15H21N3O3S
Product Type: Chemical
| API family | gliclazide |
| application(s) | pharmaceutical pharmaceutical small molecule |
| form | crystalline powder |
| format | neat |
| grade | pharmaceutical primary standard |
| InChI | 1S/C15H21N3O3S/c1-11-5-7- |
| InChI key | BOVGTQGAOIONJV-UHFFFAOYSA |
| manufacturer/tradename | BP |
| mp | 163-169 °C (lit.) |
| shelf life | limited shelf life, expiry date on the label |
| SMILES string | Cc1ccc(cc1)S(=O)(=O)NC(=O |
| storage temp. | 2-8°C |
| Application: | Gliclazide BP Reference standard, intended for use in laboratory tests only as specifically prescribed in the British Pharmacopoeia. Also used in monographs such as: |
| Application: | Used in the treatment of non-insulin dependent diabetes mellitus (NIDDM). |
| Biochem/physiol Actions: | Oxidative modification of low-density lipoprotein (LDL) plays an important role in vascular dysfunction associated with diabetes mellitus. Gliclazide is a second-generation sulfonylurea with free-radical-scavenging activity. Incubation of human aortic smooth muscle cell (HASMC) with native human LDL (100 μg/mL) in the presence of increasing concentrations of gliclazide (1 to 10 μg/mL) resulted in a dose-dependent decrease in HASMC-mediated LDL oxidation. Exposure of HASMCs to gliclazide (1 to 10 μg/mL) and native LDL (100 μg/mL) also led to a dose-dependent decrease in oxidized LDL-induced human monocyte adhesion to HASMCs. In addition, incubation of HASMCs with gliclazide dramatically reduced the ability of oxidized LDL to stimulate the proliferation of these cells. Finally, treatment of HASMCs with gliclazide resulted in a marked decrease in oxidatively modified LDL-induced monocyte chemoattractant protein (MCP)-1 and human heat shock protein 70 (HSP 70) expression, both at the gene and protein levels. These results show that gliclazide, at concentrations in the therapeutic range (5 to 10 μg/mL), is effective in vitro in reducing vascular smooth muscle cell (VSMC) dysfunction induced by oxidatively modified LDL. Administration of gliclazide to type 2 diabetic patients could form part of the strategy for the prevention and management of diabetic cardiovascular diseases |
| General description: | This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia. |
| Other Notes: | Sales restrictions may apply. |
| Packaging: | Unit quantity: 200 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia   |
| Symbol |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P301 + P312 + P330 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| mp | 163-169 °C (lit.) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352125 |